Home / Information / Alectinib
Alectinib
Alectinib is a 2nd generation TKI developed by Roche. The recommended dose is 600mg taken twice daily.
Documents
Name
Summary of Contents
Action
Final results of the phase 3 ALEX trial
NEW
Median Overall Survival of 81 months for patients starting treatment with Alectinib.
Use of Alectinib with Paxlovid
NEW
Paxlovid is a CYP3A4 inhibitor which is used to treat early Covid-19 infections.
Use of Alectinib with Semaglutide (slimming drug)
NEW
Semaglutide is a highly effective glucagon-like peptide 1 receptor agonist (GLP-1RA) for treating obesity. However, it may reduce the effectiveness of Alectinib.
It is the active ingredient in Ozempic and Wegovy.
Alectinib and Diets
This webpage contains information on whether your diet has a big effect on common lung cancer treatment.
Alectinib Dose Reduction
This webpage contains information on Alectinib dose reduction and the side effects caused by reduction.
Alectinib Induced Skin Rash
This document provides information for on patients with high grade Alectinib induced skin rashes.
Safety of Dose Escalation
This document contains information on the safety of dose escalated Alectinib in patients with ALK+ NSCLC.